Intravesical pH: A potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer

BJU International

Volumn 90, Issue 9, 2002, Pages 957-964

  Harris, N M ^a,c   Duffy, P M ^b   Crook, T J ^b   Anderson, W R ^a   Sharpe, P ^b   Hayes, M C ^b   Cooper, A J ^a   Solomon, L Z ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Bladder cancer; Confocal microscopy; Epirubicin; Flow cytometry; Multidrug resistance; Verapamil

Indexed keywords

AMRUBICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; EPIRUBICIN; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CANCER CHEMOTHERAPY; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; URINE PH; BLADDER; BLADDER TUMOR; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESISTANCE; INTRAVESICAL DRUG ADMINISTRATION; PH; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EPIRUBICIN; FLOW CYTOMETRY; HUMANS; HYDROGEN-ION CONCENTRATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TUMOR CELLS, CULTURED; URINARY BLADDER; URINARY BLADDER NEOPLASMS; VERAPAMIL;

EID: 0036884047     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02999.x     Document Type: Article

References (35)

1. Huncharek M, McGarry R. Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a metaanalysis. Anticancer Res 2001; 21: 765-9
2. Hall RR. Superficial bladder cancer. BMJ 1994; 308: 910-3
3. Richie JP. Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 1992; 19: 521-7
4. Tsushima T, Kobashi K, Akebi N et al. Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy. Gan Kagaku Ryoho 2001; 28: 483-91
5. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992; 19: 529-39
6. Duffy PM, Hayes MC. Gatrell SK, Cooper A. Smart CJ. Deterruination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Br J Urol 1996; 77: 824-9
7. Groos E, Masters JR. Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. J Urol 1986; 136: 399-402
8. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-20
9. Davies R, Budworth J. Riley J, Snowden R, Gescher A. Gant TW. Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Br J Cancer 1996: 73: 307-15
10. Scheper RJ, Broxterman HJ, Scheffer GL et al. Overexpression of a M(r) 110.000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-9
11. Flens MJ, Izquierdo MA, Scheffer GL et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-63
12. Clifford SC, Neal DE. Lunec J. High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens? Carcinogenesis 1996; 17: 601-4
13. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995; 87: 1588-92
14. Nakagawa M, Emoto A. Nasu N et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997; 157: 1260-4
15. Duffy PM. Hayes MC, Cooper A, Smart CJ. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model. Br J Urol 1996; 77: 819-23
16. McGovern F, Kachel T, Vijan S, Schiff S, Lin CW, Prout GR Jr. Establishment and characterization of a doxorubicin-resistant human bladder cancer cell line (MGH-U1R). J Urol 1988; 140: 410-4
17. Horton JK. Thimmaiah KN. Houghton JA. Horowitz ME. Houghton PJ. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 1989; 38: 1727-36
18. Long JP Jr. Prout GR Jr. Wong YK, Lin CW. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. J Urol 1990; 143: 1053-6
19. Freshney R. Culture of animal cells. A manual of basic technique. Chapt 1994. Chichester: Wiley-Liss 2002: 296-8
20. Jennings AM. Solomon LZ. Sharpe P. Hayes MC, Cooper AJ. Birch BR. Estramustine reversal of resistance to intravesical epirubicin chemotherapy. Eur Urol 1999; 35: 327-35
21. Floyd JW, Lin CW, Prout GR Jr. Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line. J Urol 1990; 144: 169-71
22. Yu DS, Sun GH, Ma CP. Chang SY. Verapamil modulation of multidrug resistance in renal cell carcinoma. J Formos Med Assoc 2000; 99: 311-6
23. Naito S, Kotoh S, Omoto T et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological Oncology Group. Cancer Chemother Pharmacol 1998: 42: 367-72
24. Harris NM, Crook T, Dyer JP et al. Intravesical MeGLA: a phase IIa efficacy study. Eur Urol 2002; 42: 39-42
25. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988; 80: 188-94
26. Cornarotti M, Tinelli S, Willmore E et al. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180). Mol Pharmacol 1996; 50: 1463-71
27. Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 1993; 67: 728-33
28. Guffy MM. North JA. Burns CP. Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 1984; 44: 1863-6
29. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Laboratory Invest 1994; 71: 583-94
30. Lobban ED, Smith BA. Hall GD et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 1998; 153: 1957-67
31. Cooper AJ, Hayes MC. Duffy PM. Davies CL. Smart CJ. Multi-drug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies. Cytotechnology 1996; 19: 181-6
32. Duffy PM, Hayes MC, Cooper A. Smart CJ. Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. Br J Cancer 1996; 74: 906-9
33. Bobichon H, Cailleret L, Ploton D, Belhoussine R, Jardillier JC. Nuclear transport as an ultimate step of multidrug resistance. Life Sci 1999; 65: 2343-9
34. Boscoboinik D. Gupta RS. Epand RM. Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells. Br J Cancer 1990; 61: 568-72
35. Hamilton G, Cosentini EP, Teleky B et al. The multidrug-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines in vitro. Anticancer Res 1993; 13: 2059-63